Following the joint project started last march, DevsHealth incorporated its first spin-out 3CL-Bio, in cooperation with Fundació Lluita contra les infeccions and IrsiCaixa. The new company will serve as the vehicle to develop a new oral COVID-19 treatment.
Last March, DevsHealth decided to start the development of a new treatment against COVID-19 in cooperation with Fundació Lluita contra les infeccions and IrsiCaixa, with a very clear objective: making an affordable treatment that can be administered orally in primary care use. This new treatment will help avoid adverse effects on health systems in future COVID-19 waves, even protecting those that for any reason cannot receive the available vaccine.
The new company, led by DevsHealth, will help increase public-private synergies, where public institutions contribute with their know-how and knowledge of medical needs, while DevsHealth in addition to the project management, contributes with its technology to develop new antiinfectious drugs. 3CLBio will also seek the necessary investments to develop the pre-clinical as well as the Phase-I of the clinical studies of the future treatment. According to Dr. Alfons Nonell-Canals, CEO of DevsHealth, «these collaborations are the way to bring together the best of both worlds, on the one hand the knowledge accumulated in a public research institution, and on the other hand the agility of a private company, especially in our case where we bring our technology combined with the agility of a start-up company»
Regarding the initial funding, not only have the three entities already contributed with their knowledge and resources, but the new project will also leverage on the previous experience of the Fundació and Dr. Clotet, president of the Fundació Lluita contra les Infeccions and Territorial Clinical Director of Infectious Diseases (Institut Català de laSalut). Dr. Clotet has years of experience in the creation and participation in different spin-offs (AlbaJuna, Aelix Therapeutics, Doole among others).
With 3CLBio, the entities want to make avery fast development possible thanks to the experience of the Fundació and IrsiCaixa with COVID, and also thanks to the technology developed by DevsHealth, able to test millions of molecules in a few days. The goal is to finish Phase-I and its licence in no more than two and a half years.
Comments